# INDICATE (NCT04423211)

> Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04423211
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: ECOG-ACRIN Cancer Research Group
- Conditions: Biochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
- Interventions: 3-Dimensional Conformal Radiation Therapy; Apalutamide; Computed Tomography; Degarelix; External Beam Radiation Therapy; Fluciclovine F18; Goserelin Acetate; Intensity-Modulated Proton Therapy; Intensity-Modulated Radiation Therapy; Leuprolide Acetate; Magnetic Resonance Imaging; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Relugolix; Stereotactic Body Radiation Therapy; Triptorelin; Volume Modulated Arc Therapy
- Enrollment: 804
- Primary outcome: Progression-free survival (PFS)
- Primary outcome: PFS prolongation in patients without PET-evidence of extrapelvic metastases
- Primary outcome: PFS prolongation in patients with PET-evidence of extrapelvic metastases
- Primary outcome: Quality of life (QOL)

## Indexed commentary on INDICATE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=indicate-nct04423211